TY - JOUR
T1 - Acute Kidney Injury, Systemic Inflammation, and Long-Term Cognitive Function
T2 - ASSESS-AKI
AU - Bhatraju, Pavan K.
AU - Zelnick, Leila R.
AU - Stanaway, Ian B.
AU - Ikizler, T. Alp
AU - Menez, Steven
AU - Chinchilli, Vernon M.
AU - Coca, Steve G.
AU - Kaufman, James S.
AU - Kimmel, Paul L.
AU - Parikh, Chirag R.
AU - Go, Alan S.
AU - Siew, Edward D.
AU - Wurfel, Mark M.
AU - Himmelfarb, Jonathan
N1 - Publisher Copyright:
Copyright © 2024 by the American Society of Nephrology.
PY - 2024/7
Y1 - 2024/7
N2 - Background Cognitive dysfunction is a well-known complication of CKD, but it is less known whether cognitive decline occurs in survivors after AKI. We hypothesized that an episode of AKI is associated with poorer cognitive function, mediated, at least in part, by persistent systemic inflammation. Methods Assessment, Serial Evaluation and Subsequent Sequelae of AKI enrolled patients surviving 3 months after hospitalization with and without AKI matched on the basis of demographics, comorbidities, and baseline kidney function. A subset underwent cognitive testing using the modified mini-mental status examination (3MS) at 3, 12, and 36 months. We examined the association of AKI with 3MS scores using mixed linear models and assessed the proportion of risk mediated by systemic inflammatory biomarkers. Results Among 1538 participants in Assessment, Serial Evaluation and Subsequent Sequelae of AKI, 1420 (92%) completed the 3MS assessment at 3 months and had a corresponding matched participant. Participants with AKI had lower 3MS scores at 3 years (difference -1.1 [95% confidence interval, -2.0 to -0.3] P = 0.009) compared with participants without AKI. A higher proportion of participants with AKI had a clinically meaningful (≥5 point) reduction in 3MS scores at 3 years compared with participants without AKI (14% versus 10%, P = 0.04). In mediation analyses, plasma-soluble TNF receptor-1 at 3 months after AKI mediated 35% (P = 0.02) of the AKI-related risk for 3MS scores at 3 years. Conclusions AKI was associated with lower 3MS scores, and Soluble TNF receptor 1 concentrations seemed to mediate a significant proportion of the risk of long-term cognitive impairment. Further work is needed to determine whether AKI is causal or a marker for cognitive impairment.
AB - Background Cognitive dysfunction is a well-known complication of CKD, but it is less known whether cognitive decline occurs in survivors after AKI. We hypothesized that an episode of AKI is associated with poorer cognitive function, mediated, at least in part, by persistent systemic inflammation. Methods Assessment, Serial Evaluation and Subsequent Sequelae of AKI enrolled patients surviving 3 months after hospitalization with and without AKI matched on the basis of demographics, comorbidities, and baseline kidney function. A subset underwent cognitive testing using the modified mini-mental status examination (3MS) at 3, 12, and 36 months. We examined the association of AKI with 3MS scores using mixed linear models and assessed the proportion of risk mediated by systemic inflammatory biomarkers. Results Among 1538 participants in Assessment, Serial Evaluation and Subsequent Sequelae of AKI, 1420 (92%) completed the 3MS assessment at 3 months and had a corresponding matched participant. Participants with AKI had lower 3MS scores at 3 years (difference -1.1 [95% confidence interval, -2.0 to -0.3] P = 0.009) compared with participants without AKI. A higher proportion of participants with AKI had a clinically meaningful (≥5 point) reduction in 3MS scores at 3 years compared with participants without AKI (14% versus 10%, P = 0.04). In mediation analyses, plasma-soluble TNF receptor-1 at 3 months after AKI mediated 35% (P = 0.02) of the AKI-related risk for 3MS scores at 3 years. Conclusions AKI was associated with lower 3MS scores, and Soluble TNF receptor 1 concentrations seemed to mediate a significant proportion of the risk of long-term cognitive impairment. Further work is needed to determine whether AKI is causal or a marker for cognitive impairment.
UR - http://www.scopus.com/inward/record.url?scp=85198675401&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85198675401&partnerID=8YFLogxK
U2 - 10.2215/CJN.0000000000000473
DO - 10.2215/CJN.0000000000000473
M3 - Article
C2 - 38728094
AN - SCOPUS:85198675401
SN - 1555-9041
VL - 19
SP - 829
EP - 836
JO - Clinical Journal of the American Society of Nephrology
JF - Clinical Journal of the American Society of Nephrology
IS - 7
ER -